MISSISSAUGA, ON, Jan. 20, 2012 /CNW/ - Covalon Technologies Ltd. (the
"Company" or "Covalon") (TSXV: COV), an advanced medical technologies
company, today announced it is presenting its latest line of advanced
wound care and medical coating products, including ColActive® Plus Ag
from January 23rd to 26th at the Annual Arab Health Congress in Dubai,
U.A.E. Now in its 37th year, Arab Health provides an opportunity for
the world's leading medical products manufacturers, wholesalers and
distributors to meet the 65,000 medical and scientific community
attendees from the Middle East and beyond.
Since announcing a multi-year distribution agreement with a Canadian
distributor that will export and distribute Covalon's ColActive Plus Ag
wound care dressings in certain regions of the Middle East, the
interest from medical companies to introduce Covalon products to the
entire region has increased significantly. ColActive Plus Ag, a
patented wound dressing, is available for distribution and has been
cleared for regulatory purposes in the United States, Canada and other
jurisdictions. Covalon is also showcasing SurgiClear™ and IV Clear™ -
breathable, clear film antimicrobial surgical wound and IV securement
dressings, along with lubricious and antimicrobial coated catheters
which are available for distribution in North America, Middle East and
"We are extremely excited to present at this year's Arab Health
Congress," said Brian Pedlar, Covalon's Chief Executive Officer.
"There has been great excitement and interest about the ColActive Plus
family of advanced wound dressings from international clinicians and
medical product companies who are looking to license new breakthrough
To learn more about Covalon's products and services, please visit us at
booth SAD 58 in the Dubai World Trade Centre from January 23rd to 26th or contact Brian Pedlar, CEO Covalon Technologies Ltd. at firstname.lastname@example.org.
Covalon Technologies Ltd. researches, develops and commercializes new
healthcare technologies that help save lives around the world.
Covalon's patented technologies, products and services address the
advanced healthcare needs of medical device companies, healthcare
providers and individual consumers. Covalon's technologies are used to
prevent, detect and manage medical conditions in specialty areas such
as wound care, tissue repair, infection control, disease management,
medical device coatings and biocompatibility. To learn more about
Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as "seek", "anticipate", "plan, "estimate", "expect",
"intend" and statements that an event or result "may", "will",
"should", "could" or "might" occur or be achieved and other similar
expressions. These forward-looking statements involve risk and
uncertainties, including the difficulty in predicting product
approvals, acceptance of and demands for new products, the impact of
the products and pricing strategies of competitors, delays in
developing and launching new products, the regulatory environment,
fluctuations in operating results and other risks, any of which could
cause results, performance, or achievements to differ materially from
the results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific to
the Company. Investors should consult the Company's ongoing quarterly
filings for additional information on risks and uncertainties relating
to these forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements whether as
a result of new information, further events or otherwise.
SOURCE Covalon Technologies Ltd.
For further information:
CEO, Covalon Technologies Ltd.
T: (905) 568-8400 x 233
F: (905) 568-5200